Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Net income
Gilead Sciences, Inc.'s net income for fiscal 2025 was $8.5B, up 1,672.9% from $480.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.2B. Over the past ten years it has ranged from $89.0M (fiscal 2020) to $18.1B (fiscal 2015); the current reading is higher than 82% of that period. Gilead Sciences, Inc. ranks 21st of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $8.5B | 1,672.92% |
| FY2024 | $480.0M | (91.45%) |
| FY2023 | $5.6B | 22.93% |
| FY2022 | $4.6B | (26.37%) |
| FY2021 | $6.2B | 6,867.42% |
| FY2020 | $89.0M | (98.34%) |
| FY2019 | $5.4B | (1.76%) |
| FY2018 | $5.5B | 17.57% |
| FY2017 | $4.6B | (65.57%) |
| FY2016 | $13.5B | (25.51%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$10.5B | — |
| Mar 2026 | $2.0B | (7.42%) |
| Dec 2025 | $2.2B | (28.47%) |
| Sep 2025 | $3.1B | 55.71% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| AMGN Amgen Inc. compare | $8.7B |
| GSK GSK PLC Sponsored ADR compare | $6.9B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GILD
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement